

## PRESS RELEASE

### **Piramal Pharma Solutions' Aurora, Canada Facility Implements the POD Method to Optimize Project Execution**

- *Piramal Pharma Solutions has implemented the PODs (Plan, Own, and Deliver) Project Execution System at its API facility in Aurora, Canada.*
- *The system centers around cross-functional teams composed of eight to ten subject matter experts from various departments, collaborating on the end-to-end execution of their assigned projects.*
- *The PODs improve communication, streamline workflows, and empower ownership and accountability, ensuring flawless project execution.*

**Mumbai, India | October 7, 2025:** Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), has transformed operations at its world-class drug substance facility in Aurora, Canada by introducing the PODs (Plan, Own, and Deliver) Project Execution System. The Aurora site implemented this innovative system to execute seamless deliveries to customers amidst a growing pipeline and increased client demand in alignment with Piramal Pharma Solutions' long-standing commitment to best practices and continuous improvement.

The Aurora facility developed the PODs Project Execution System to empower collaboration, accountability, and ownership, ensuring the flawless execution of the site's project portfolio. At the heart of the PODs Project Execution System are the individual PODs, which are cross-functional teams composed of eight to ten subject matter experts from various departments, collaborating on the end-to-end execution of their assigned projects. Each POD collaborates to manage a portfolio of development and commercial projects, meeting daily in the facility's Capsule of Creativity to align their actions with project goals, measure success metrics, and tackle challenges in real-time. The PODs also conduct weekly check-ins with stakeholders to provide visibility into current risks and opportunities.

The PODs don't just enhance speed and efficiency; they also help Piramal Pharma Solutions deliver on its promise to patients. Since launching the PODs, the Aurora facility has freed up and redeployed over 1,200 hours of employee time, significantly reduced adverse quality events, and enhanced adaptability by identifying scope changes early on. These benefits enable Piramal Pharma Solutions to achieve project goals swiftly and precisely, helping clients rapidly deliver their life-saving therapies to patients worldwide.

"We are constantly on the lookout for ways to improve our operations, and the Program Management of our client's projects is anchored in this commitment to continuous improvement," said **Herve**

**Berdou, Chief Operating Officer, Piramal Pharma Solutions.** “The Aurora facility has embraced this journey of excellence in Delivery by strengthening its Internal Projects Teams, which they’ve locally named PODs, representing their drive to plan, own, and deliver for our clients.”

.....

### **About Piramal Pharma Solutions**

Piramal Pharma Solutions (PPS) is a Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our customers through a globally integrated network of facilities in North America, Europe, and Asia. This enables us to offer a comprehensive range of services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms. We also offer specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.

For more information visit: [Piramal Pharma Solutions](#) | [LinkedIn](#) | [Facebook](#) | [X](#)

### **About Piramal Pharma Limited**

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17\* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

\* Includes one facility via PPL’s minority investment in Yapan Bio.

---

### **For Investor Queries:**

Gagan Borana

Investor Relations & Enterprise Risk Management

[gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)

### **For Media Queries:**

Madiha Vahid

Lead – Branding & Communications

[madiha.vahid@piramal.com](mailto:madiha.vahid@piramal.com)